DNA Repair Deficiencies and the Promise of PARP Inhibition in Prostate Cancer: Clinical Implications

In this online educational program CCO&rsquo s expert faculty explore optimal care for patients with prostate cancer focusing on DNA repair deficiencies genetic testing and best practice for the use of PARP inhibitors.

Share

Program Content

Activities

DNA Repair Mutations in PCa
Overview of DNA Repair Mechanisms and the Molecular Landscape of Advanced Prostate Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2018

Expires: May 24, 2019

Genetic Testing in PCa
The Intersection of Germline and Somatic Genetic Testing in Advanced Prostate Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2018

Expires: May 24, 2019

PARPi Therapy in PCa
DNA Repair Defects as a Therapeutic Target in Advanced Prostate Cancer: The Role of PARP Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 25, 2018

Expires: May 24, 2019

Activities

Urology 2018: PARPi in PCa
DNA Repair Deficiencies and the Promise of PARP Inhibition in Prostate Cancer: Clinical Implications
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2018

Expires: June 21, 2019

Faculty

cover img faculity

William B. Isaacs, PhD

Professor
Department of Urology
Johns Hopkins School of Medicine
Baltimore, Maryland

cover img faculity

Todd M. Morgan, MD

Associate Professor
Department of Urology
University of Michigan
Ann Arbor, Michigan

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca